Intuitive Surgical (NASDAQ:ISRG) Price Target Increased to $280.00 by Analysts at JPMorgan Chase & Co.

Intuitive Surgical (NASDAQ:ISRGGet Rating) had its target price increased by stock analysts at JPMorgan Chase & Co. from $250.00 to $280.00 in a report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 6.83% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Intuitive Surgical in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Stifel Nicolaus increased their price objective on Intuitive Surgical from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, September 9th. Truist Financial increased their price objective on Intuitive Surgical from $260.00 to $300.00 in a research report on Monday, November 14th. Wells Fargo & Company cut their price objective on Intuitive Surgical from $265.00 to $248.00 and set an “overweight” rating for the company in a research report on Wednesday, October 19th. Finally, Citigroup cut their price objective on Intuitive Surgical from $243.00 to $237.00 in a research report on Wednesday, October 5th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $261.05.

Intuitive Surgical Price Performance

ISRG opened at $262.11 on Friday. The company has a market capitalization of $92.63 billion, a price-to-earnings ratio of 69.16, a price-to-earnings-growth ratio of 5.74 and a beta of 1.38. Intuitive Surgical has a 1-year low of $180.07 and a 1-year high of $369.21. The business has a 50 day moving average price of $217.25 and a two-hundred day moving average price of $216.71.

Intuitive Surgical (NASDAQ:ISRGGet Rating) last released its earnings results on Tuesday, October 18th. The medical equipment provider reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.07. The firm had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.52 billion. Intuitive Surgical had a return on equity of 11.54% and a net margin of 22.52%. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.04 earnings per share. Equities analysts expect that Intuitive Surgical will post 3.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 8,000 shares of the stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $250.06, for a total transaction of $2,000,480.00. Following the transaction, the executive vice president now directly owns 217 shares of the company’s stock, valued at $54,263.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, Director Amal M. Johnson sold 6,375 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $210.76, for a total transaction of $1,343,595.00. Following the completion of the sale, the director now directly owns 11,224 shares in the company, valued at $2,365,570.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 8,000 shares of the company’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $250.06, for a total transaction of $2,000,480.00. Following the sale, the executive vice president now owns 217 shares of the company’s stock, valued at $54,263.02. The disclosure for this sale can be found here. Insiders have sold 72,953 shares of company stock valued at $15,867,996 over the last three months. 0.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds have recently bought and sold shares of ISRG. RB Capital Management LLC boosted its holdings in Intuitive Surgical by 4.4% during the first quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after acquiring an additional 73 shares during the period. IFM Investors Pty Ltd boosted its holdings in Intuitive Surgical by 25.6% during the first quarter. IFM Investors Pty Ltd now owns 60,188 shares of the medical equipment provider’s stock valued at $18,158,000 after acquiring an additional 12,269 shares during the period. Integrated Advisors Network LLC boosted its holdings in Intuitive Surgical by 35.9% during the first quarter. Integrated Advisors Network LLC now owns 1,318 shares of the medical equipment provider’s stock valued at $398,000 after acquiring an additional 348 shares during the period. DAVENPORT & Co LLC lifted its stake in shares of Intuitive Surgical by 10.2% in the first quarter. DAVENPORT & Co LLC now owns 1,071 shares of the medical equipment provider’s stock valued at $323,000 after buying an additional 99 shares during the period. Finally, Brandywine Oak Private Wealth LLC lifted its stake in shares of Intuitive Surgical by 16.5% in the first quarter. Brandywine Oak Private Wealth LLC now owns 811 shares of the medical equipment provider’s stock valued at $244,000 after buying an additional 115 shares during the period. 82.44% of the stock is currently owned by institutional investors.

About Intuitive Surgical

(Get Rating)

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Further Reading

Analyst Recommendations for Intuitive Surgical (NASDAQ:ISRG)

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.